… Vascular endothelial growth factor (VEGF)–targeted therapy … not respond to VEGF-targeted
therapy when used as a single … of benefit from VEGF-targeted therapy can be relatively short …

… A growing understanding of the underlying biology of RCC has identified vascular endothelial
growth factor (VEGF) as a logical therapeutic target. Therapy directed against the biologic …

… endothelial growth factor (VEGF) targeted therapy, … -targeted therapies, and their effect
on perioperative wound complications. Surgery in patients receiving VEGF-targeted therapies …

… associated with expression of vascular endothelial growth factor (VEGF). Recently, VEGF-targeted
therapies have been identified as a promising therapeutic approach. Three agents …

… Recent advances in the development of targeted therapies for the treatment of cancer have
… The VEGF family of molecules currently consists of six growth factors, including VEGF-A, …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is
frequently expressed in epithelial tumors. The EGFR was the first receptor to be proposed as a …

… endothelial growth factor (VEGF)–targeted therapy in … metastatic RCC respond to VEGF-targeted
therapy. On the basis of … received VEGF-targeted therapy were retrospectively identified, …

… received sunitinib and other active, targeted therapy on progression, likely under powering
this … controls support the finding that targeted therapy has meaningfully extended the lives of …

… Five independent prognostic factors for predicting PFS were identified and were used to …
RCC who received VEGF-targeted therapies into 3 risk groups. These prognostic factors can be …

… Vascular endothelial growth factor targeted therapy is a standard of care in patients with
metastatic renal cell carcinoma. The role of cytoreductive nephrectomy in the era of novel …